Compare BCBP & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | IMUX |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.5M | 155.8M |
| IPO Year | 2005 | 2013 |
| Metric | BCBP | IMUX |
|---|---|---|
| Price | $8.18 | $7.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $8.95 | ★ $43.09 |
| AVG Volume (30 Days) | ★ 453.6K | 392.9K |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $0.51 |
| 52 Week High | $11.71 | $17.43 |
| Indicator | BCBP | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 32.07 | 25.06 |
| Support Level | $8.11 | $0.83 |
| Resistance Level | $8.84 | $15.82 |
| Average True Range (ATR) | 0.17 | 0.63 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 7.14 | 4.36 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.